{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023492","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.242778+00:00","generated_at":"2026-05-16T19:53:02.934155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"confidence":"high","headline":"Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR","bullets":["Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.","Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.","Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.","FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.","R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023492","json":"https://secwatch.observer/filing/0001493152-25-023492.json","markdown":"https://secwatch.observer/filing/0001493152-25-023492.md","text":"https://secwatch.observer/filing/0001493152-25-023492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/0001493152-25-023492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:53:02.934155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}